FluoroPharma Medical, Inc., formerly Commercial E-Waste Management Inc., is a biopharmaceutical company specializing in discovering, developing and commercializing molecular imaging pharmaceuticals with applications in the area of cardiology. The Company operates through biopharmaceutical research and development segment. It is focused on the development of cardiovascular imaging agents that can detect and assess acute and chronic forms of coronary artery disease (CAD). It has two clinical-stage molecular imaging pharmaceutical product candidates: Flourine-18 (18-F) TPP (BFPET), which includes a ((18F)-labeled cationic lipophilic tetraphenylphosphonium ion (18-F TPP) as an imaging agent designed for use in stress-testing for patients with presumptive or proven CAD, and 18-F FCPHA (CardioPET), which includes Trans-9-(18F)-Fluoro-3, 4-Methyleneheptadecanoic Acid (18-F FCPHA) as a molecular imaging agent designed to assess myocardial blood flow and metabolism in patients with CAD.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:FPMI
- CUSIP: N/A
- Web: www.fluoropharma.com
- Market Cap: $1.03 million
- Outstanding Shares: 34,262,000
- 50 Day Moving Avg: $0.04
- 200 Day Moving Avg: $0.07
- 52 Week Range: $0.02 - $0.29
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.000
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: ($0.30) per share
- Price / Book: -0.09
- EBIDTA: ($2,160,000.00)
- Return on Assets: -608.29%
- Average Volume: 34,473 shs.
- Beta: 0.75
Frequently Asked Questions for FluoroPharma Medical (OTCMKTS:FPMI)
What is FluoroPharma Medical's stock symbol?
FluoroPharma Medical trades on the OTCMKTS under the ticker symbol "FPMI."
How were FluoroPharma Medical's earnings last quarter?
FluoroPharma Medical Inc. (OTCMKTS:FPMI) announced its earnings results on Friday, August, 14th. The company reported ($0.05) EPS for the quarter, topping the Zacks' consensus estimate of ($0.06) by $0.01. View FluoroPharma Medical's Earnings History.
Who are some of FluoroPharma Medical's key competitors?
Some companies that are related to FluoroPharma Medical include Affymax (AFFY), Adeptus Health (ADPT), DNIB Unwind (BIND), Echo Therapeutics (ECTE), Epirus Biopharmaceuticals (EPRS), Luxottica Group SpA (LUX), Mast Therapeutics (MSTX), Parnell Pharmaceuticals Holdings Ltd (PARN), Secure Point Technologies (IMSC), Sunshine Heart (SSH), Tetralogic Pharmaceuticals Corp (TLOG) and Unilife Corp (UNIS).
Who are FluoroPharma Medical's key executives?
FluoroPharma Medical's management team includes the folowing people:
- Walter W. Witoshkin, Interim Chairman of the Board, Independent Director
- Thomas H. Tulip Ph.D., President, Chief Executive Officer, Director
- Tamara Rhein, Chief Financial Officer
- W. Austin Lewis IV, Director
How do I buy FluoroPharma Medical stock?
Shares of FluoroPharma Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is FluoroPharma Medical's stock price today?
MarketBeat Community Rating for FluoroPharma Medical (OTCMKTS FPMI)MarketBeat's community ratings are surveys of what our community members think about FluoroPharma Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of FluoroPharma Medical stock can currently be purchased for approximately $0.03.
Consensus Ratings for FluoroPharma Medical (OTCMKTS:FPMI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for FluoroPharma Medical (OTCMKTS:FPMI)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for FluoroPharma Medical (OTCMKTS:FPMI)Earnings History by Quarter for FluoroPharma Medical (OTCMKTS FPMI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for FluoroPharma Medical (OTCMKTS:FPMI)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for FluoroPharma Medical (OTCMKTS:FPMI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for FluoroPharma Medical (OTCMKTS:FPMI)
Insider Ownership Percentage: 36.90%Insider Trades by Quarter for FluoroPharma Medical (OTCMKTS:FPMI)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/7/2014||Johan M Spoor||CEO||Buy||10,000||$0.50||$5,000.00|| |
|11/26/2012||Johan M Spoor||CEO||Buy||10,000||$0.76||$7,600.00|| |
|9/12/2012||Johan M Spoor||CEO||Buy||50,000||$0.80||$40,000.00|| |
Headline Trends for FluoroPharma Medical (OTCMKTS:FPMI)
Latest Headlines for FluoroPharma Medical (OTCMKTS:FPMI)
|FluoroPharma and Philips Collaborate on Image Management for CardioPET Phase II Clinical Trial|
finance.yahoo.com - April 7 at 9:51 AM
|FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders|
biz.yahoo.com - March 2 at 5:31 PM
|FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit|
biz.yahoo.com - December 6 at 11:00 AM
|FluoroPharma Medical (FPMI), Philips (PHG) Enter CardioPET Phase II Image Management Collaboration|
www.streetinsider.com - October 19 at 5:28 PM
|FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Of|
biz.yahoo.com - September 30 at 5:24 PM
|FluoroPharma Announces CardioPET Phase II Results at the 21st American Society of Nuclear Cardiology (ASNC) Meeting|
finance.yahoo.com - September 26 at 5:15 PM
|FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles of|
biz.yahoo.com - August 18 at 5:04 PM
FluoroPharma Medical (FPMI) Chart for Tuesday, July, 25, 2017